[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of ciclesonide inhalation aerosol in healthy subjects under fasting conditions

主要目的：健康受试者空腹状态下，经口吸入给药单剂量环索奈德吸入气雾剂（受试制剂T，上海上药信谊药厂有限公司生产，规格：160μg/揿）与环索奈德吸入气雾剂（参比制剂R，Covis Pharma Gmbh生产，商品名：Alvesco®，规格：160μg/揿）后，本次试验考察空腹条件下受试制剂与参比制剂在人体内的吸收速度和吸收程度，评价受试制剂与参比制剂是否具有生物等效性。次要目的：观察受试制剂环索奈德吸入气雾剂和参比制剂环索奈德吸入气雾剂（Alvesco®）在健康受试者中的安全性。

[Translation]

Primary objective: After oral administration of a single dose of ciclesonide inhalation aerosol (test preparation T, produced by Shanghai SPH Xinyi Pharmaceutical Co., Ltd., specification: 160μg/press) and ciclesonide inhalation aerosol (reference preparation R, produced by Covis Pharma Gmbh, trade name: Alvesco®, specification: 160μg/press) to healthy subjects in the fasting state, this study investigates the absorption rate and extent of the test preparation and the reference preparation in the human body under fasting conditions, and evaluates whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of the test preparation ciclesonide inhalation aerosol and the reference preparation ciclesonide inhalation aerosol (Alvesco®) in healthy subjects.

Start Date21 Nov 2024

Sponsor / Collaborator

Shanghai Sine Pharmaceutical Co. Ltd.

CTR20233942

/ CompletedNot Applicable

环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验

[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of ciclesonide aerosol in healthy subjects under fasting conditions

主要目的：健康受试者空腹状态下，经口吸入单次给药环索奈德气雾剂（受试制剂T，上海上药信谊药厂有限公司生产，规格：80μg/揿）与环索奈德气雾剂（参比制剂R，Covis Pharma Gmbh生产，商品名：Alvesco®，规格：80μg/揿）后，考察空腹条件下受试制剂与参比制剂在人体内的吸收速度和吸收程度，评价受试制剂与参比制剂是否具有生物等效性。次要目的：观察受试制剂环索奈德气雾剂和参比制剂环索奈德气雾剂（Alvesco®）在健康受试者中的安全性。

[Translation]

Primary objective: To investigate the absorption rate and extent of the test preparation and the reference preparation in the human body after oral inhalation of a single dose of ciclesonide aerosol (test preparation T, produced by Shanghai SPH Xinyi Pharmaceutical Co., Ltd., specification: 80μg/press) and ciclesonide aerosol (reference preparation R, produced by Covis Pharma Gmbh, trade name: Alvesco®, specification: 80μg/press) in healthy subjects under fasting conditions, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of the test preparation ciclesonide aerosol and the reference preparation ciclesonide aerosol (Alvesco®) in healthy subjects.

Start Date12 Dec 2023

Sponsor / Collaborator

Shanghai Sine Pharmaceutical Co. Ltd.

EUCTR2020-002208-37-DK

/ TerminatedPhase 2IIT

The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19.

Start Date29 Apr 2021

Sponsor / Collaborator-

100 Clinical Results associated with Ciclesonide

100 Translational Medicine associated with Ciclesonide

100 Patents (Medical) associated with Ciclesonide

616

Literatures (Medical) associated with Ciclesonide

01 Feb 2026·BMJ Evidence-Based Medicine

Adverse events of inhaled corticosteroids in adult patients with asthma or chronic obstructive pulmonary disease: pairwise, network and dose–response meta-analyses

Review

Author: Wang, Guojun ; Peng, Li ; Pu, Xiaofeng ; Jiang, Xinrui ; Huang, Yunbei ; Zhang, Yinhui ; Zhang, Zhengji ; Wang, Maolin ; Xu, Mengyao

Objectives:

This study aimed to evaluate the associations between inhaled corticosteroids (ICSs) and adverse events (AEs) in adults with asthma or chronic obstructive pulmonary disease (COPD) and to explore variations by ICS type and dosage.

Design and setting:

Medline/PubMed, Embase, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov were searched from inception to 20 February 2025. Data extraction and synthesis were performed, estimating risk ratios (RRs) with 95% confidence intervals (CI) or credible intervals (CrI) through pairwise and network meta-analysis (NMA), and an NMA using the Emax model was employed to find the dose–response relationships of the AEs of each ICS. Risk of bias was evaluated across both pairwise and NMAs. The certainty of evidence, based on the GRADE approach, was assessed exclusively for the NMA estimates.

Participants:

Adults diagnosed with asthma or COPD treated with ICSs compared with non-ICS controls or those receiving different types or doses of ICSs.

Main outcome measures:

The primary outcomes were AEs, including pneumonia, oral candidiasis, upper respiratory tract infection (URTI), fracture, diabetes, cataract and plasma cortisol abnormalities. Secondary outcomes included efficacy-related endpoints: asthma exacerbations, COPD exacerbations and all-cause mortality.

Results:

129 trials (120 900 participants) were included. According to pairwise meta-analysis, ICSs were associated with a higher risk of pneumonia (RR 1.49, 95% CI 1.38 to 1.61) and oral candidiasis (RR 2.29, 95% CI 2.01 to 2.60) and with a slightly higher risk of URTI (RR 1.17, 95% CI 1.10 to 1.25), compared with control. Besides, ICSs were linked to a reduced risk of asthma exacerbations (RR 0.30, 95% CI 0.20 to 0.45) and COPD exacerbations (RR 0.90, 95% CI 0.86 to 0.94) vs control. The results of the NMA that explored differences by ICS type showed that beclomethasone and fluticasone increased pneumonia risk compared with control, with absolute risk increases of up to 2.3%. Fluticasone also showed a slightly higher pneumonia risk than budesonide. Besides, mometasone, beclomethasone, budesonide and fluticasone were associated with increased risk of oral candidiasis, with the highest increase observed for mometasone (4.3%). In contrast, ciclesonide consistently showed lower risk across comparisons, reducing oral candidiasis by up to 4.5% with other ICSs. Fluticasone modestly increased URTI, while ciclesonide reduced it. Budesonide and mometasone were also associated with a small increase in cataract risk. Most of the outcomes reported here were supported by moderate- to high-certainty evidence. Furthermore, the dose–response relationship estimated from the Emax model indicated significant associations between fluticasone dose and the risks of pneumonia and URTI, between multiple ICS doses and oral candidiasis and between budesonide dose and cataract.

Conclusions:

ICSs are correlated with the escalated risk of pneumonia, oral candidiasis and URTI in adult patients with asthma or COPD, but ICSs could reduce asthma exacerbations and COPD exacerbations. Fluticasone, beclomethasone, budesonide and mometasone are independently linked to certain AEs, and some Emax dose–response relationships are detected.Our findings may help guide individualised ICS use by informing benefit-risk considerations across various formulations and dosing regimens.

PROSPERO registration number:

CRD42024527797.

01 Feb 2026·OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Investigating the Challenges of Managing Coexisting Subglottic Stenosis and Bronchopulmonary Diseases Medically Using Computational Modeling

Article

Author: Gao, Kerry ; Luzum, Nathan A. ; Frank‐Ito, Dennis O. ; Cohen, Seth

Abstract:

Objective:

Subglottic stenosis (SGS) coexists with bronchopulmonary disease, complicating topical therapy given the distinct anatomical targets. Optimizing inhaled medication delivery to both regions remain a therapeutic challenge. This study evaluates the ability of orally inhaled aerosol particles to achieve dual‑site deposition in SGS and bronchopulmonary regions.

Study Design:

Computational modeling of orally inhaled drug particle delivery.

Setting:

Academic Medical Center.

Methods:

Digitally modified airways simulating 8 SGS variants, combining McCaffrey Stage I (5 mm) and II (15 mm) subglottic lengths with Cotton‑Myer Grade I (10%, 30%), Grade II (60%), and Grade III (90%) luminal constrictions. Oral inhalation at 15 L/min and particle transport were simulated for fluticasone propionate (FP; mean aerosol velocity 9.19 m/s, particle size range 1‐8 μm) and ciclesonide (CIC; mean aerosol velocity 4.26 m/s, particle size range 1‐4 μm) inhaler characteristics, and 6 particle‑size distributions M 1 (1‐5 μm), M 2 (6‐10 μm), M 3 (1‐10 μm) while maintaining the respective parent (CIC and FP) mean aerosol velocity.

Results:

In the normal airway, CIC and FP inhalers achieved >80% bronchial deposition but ≤0.02% subglottic delivery. Among modified devices, M 2 CIC optimized dual targeting, providing the highest subglottic deposition (0.09%) with preserved bronchial efficiency (69.46%). In SGS models, M 2 CIC and M 2 FP consistently achieved the most balanced delivery, with maximum deposition of M 2 CIC = 8.4% and M 2 FP = 7.86% at subglottic region, and M 2 CIC = 69.89% and M 2 FP = 61.02% at bronchial site. M 3 variants offered intermediate dual deposition at advanced and Grade III stenosis stages.

Conclusion:

M 2 CIC and M 2 FP inhaler modifications optimized dual‐site supporting tailored device strategies for SGS with coexisting bronchopulmonary disease.

01 Jan 2026·CYTOKINE

Drug repurposing for cytokine storm: baricitinib, ciclesonide, and acalabrutinib modulate cytokine release in a translational in vitro lymphoblastoid cell line model

Article

Author: Markovič, Tijana ; Kandušer, Maša ; Hiti, Luka ; Mlinarič-Raščan, Irena

Cytokine storm, a life-threatening hyperinflammatory response seen in severe infections like COVID-19, autoimmune diseases, and certain therapies, remains difficult to treat due to limited approved therapeutics. To support preclinical drug development and repurposing in line with 3R principles, we present a novel in vitro model for screening of cytokine-modulating compounds. Herein, we demonstrate that lymphoblastoid cell lines (LCL cells), derived from healthy donors, provide a translationally relevant and phenotypically diverse platform for cytokine profiling and drug screening. Upon stimulation with PMA/ionomycin, LCL cells exhibited a robust secretion of pro-inflammatory (IL-6, IL-8, TNF-α) and anti-inflammatory (IL-10) cytokines, closely mirroring the cytokine profile of activated whole blood. Compared to established immune cell lines THP-1 and Jurkat, LCL cells showed broader cytokine responses and retained interindividual variability. We validated the model for cytokine-modulating drug screening using two well-established immunosuppressants, dexamethasone and cyclosporin A. Dexamethasone reduced IL-6 by 21 %, IL-8 by 71 %, IL-12 by 68 %, TNF-α by 83 %, and increased IL-10 by 51 %. Cyclosporin A lowered IL-6 by 34 %, IL-8 by 69 %, IL-10 by 48 %, and TNF-α by 41 %. Subsequently, we tested a panel of clinically investigated COVID-19 therapies, selected based on a comprehensive literature review. Ciclesonide and acalabrutinib showed strong suppression of all measured cytokines by more than 60 %, while baricitinib, which has become a standard of care for severe COVID-19, reduced IL-6 by 70 %, IL-12 by 68 %, and TNF-α by 47 %, but had minimal effect on IL-8. Notably, LCL cells retained interindividual variability, as demonstrated by diverse cytokine as well as divergent NF-κB nuclear translocation responses, supporting the model's capacity to reveal real-world patient heterogeneity. Collectively, our findings establish LCL cells as a reproducible, immunologically responsive, and patient-representative platform for cytokine storm research and high-content drug testing, providing both mechanistic insight and translational relevance.

News (Medical) associated with Ciclesonide

12 May 2023

·www.drugs.com

Get Relief With the Most Common Asthma Medications

FRIDAY, May 12, 2023 -- Receiving a diagnosis of asthma may be frightening, but learning what the treatment options are can help alleviate the anxiety that comes with diagnosis. Depending on the severity, certain asthma medications may help you manage your symptoms. Here, experts break down the most common long-term and quick-acting medications for asthma, how they work and potential side effects. Long-term medications These drugs are ones the patient takes daily as a means of controlling asthma and preventing asthma attacks. These can be in pill form or used as inhalers. Bronchodilators: Long-acting beta-2 agonists (LABA) relax the muscle bands around your airway (bronchi), making it easier to get air in and mucus out. These medications for asthma are taken twice a day through an inhaler and last up to 12 hours, according to the Cleveland Clinic . LABA medications should be given with a corticosteroid. (See combination medications below.) The main side effects of LABA medications are nervous or shaky feelings, hyperactivity, overexcitement, increased heart rate, upset stomach and trouble sleeping. Salmeterol (Serevent) Formoterol (Foradil) Long-acting muscarinic antagonists (LAMA) also relax the muscle bands around your airway, the National Heart, Lung, and Blood Institute (NHLBI) says. This asthma medication is used if the steroid/LABA combination doesn’t give enough relief. Do not use this medication if you have glaucoma or are at risk of urinary retention. Tiotropium bromide (Respimat) Theophylline. While not used often, theophylline can be useful in relaxing the airways and preventing reactions to irritants. It is taken as a pill and used for mild asthma symptoms. You may need to have blood tests drawn on a regular basis to make sure the level of medication is correct, the Mayo Clinic says. Side effects are the same as the other bronchodilators, but may also include chest pain or discomfort, dizziness, fainting, increase in urine volume or seizures. Theophylline (Theo-24, Theo-Dur, Slo-Bid, and others) Corticosteroids: Corticosteroids are steroids that reduce inflammation in the airways, according to the NHLBI. They may be taken as a pill, although very few patients are on the pill for long term. It is frequently used in an inhaler, often combined with a LABA. Side effects from the inhaled form are thrush (a mouth infection) and a hoarse voice. Inhaled corticosteroids include: Fluticasone (Flovent HFA, Arnuity Ellipta, others) Budesonide (Pulmicort Flexhaler) Mometasone (Asmanex Twisthaler) Beclomethasone (Qvar RediHaler) Ciclesonide (Alvesco) Combination asthma medications (Corticosteroid and LABA): Fluticasone and salmeterol (Advair) Budesonide and formoterol (Symbicort) Fluticasone and Vilanterol (Breo) Leukotriene modifiers reduce swelling and help keep your airways open for up to 24 hours. According to Mayo Clinic, these medications block the effects of leukotrienes, immune system chemicals that cause asthma symptoms. Side effects are uncommon, but may include nausea, headache, tiredness or diarrhea. Montelukast (Singulair) Zafirlukast (Accolate) Zileuton (Zyflo) Quick-acting asthma medications These are a group of medications that are used when a patient has a flare-up or an asthma attack. Inhaled short-acting beta2-agonists (SABAs) open the airways so air can flow through them during an asthma attack. They start working within 15 to 20 minutes and continue to work for 4 to 6 hours, according to the Cleveland Clinic. Side effects can include tremors, rapid heartbeat, allergic reactions, muscle pain, worsening breathing, dry mouth, headache, sore throat or trouble sleeping. Inhaled forms of SABA medications include: Albuterol (Ventolin) Levalbuterol (Xopenex) Albuterol and ipratropium bromide combination (DuoNeb) Corticosteroids. Oral corticosteroids are usually prescribed for short-term use to help a patient overcome a flare-up. This type of medication quickly reduces swelling and inflammation in the airways. Side effects include: Cataracts, osteoporosis, weight gain, high blood sugar, increased risk of infections, thinning bones and fractures, thin skin, bruising and slower wound healing, mood swings, depression and aggressive behavior. Prednisone (Deltasone, Prednicot, and others ) Methylprednisolone (Medrol, Solu-Medrol, Depo-Medrol) Short-acting anticholinergic bronchodilators help open the airways quickly. This medicine may be less effective than SABAs, but it is an option for people who experience side effects with other medications, the Cleveland Clinic says. Side effects you may experience with these inhalers are dry throat, eyes and nose; unusual taste; nausea and vomiting; or temporary blurred vision if the medicine gets in your eyes. Ipratropium bromide (Atrovent) Tiotropium bromide (Spiriva Respimat) Corticosteroid reliever. In January 2023, the FDA approved Airsupra, which can be used as needed to prevent bronchoconstriction and asthma attacks. In a study conducted before the approval, the risk of severe asthma exacerbation was significantly lower with a fixed-dose combination of albuterol and budesonide than with as-needed use of albuterol alone. Most common side effects are headache, oral yeast infection, cough, and difficulty speaking. Airsupra (albuterol-budesonide) Posted May 2023

Drug Approval

01 Nov 2021

·www.biospace.com

AstraZeneca Purges Two Respiratory Medicines in Big Day for Covis

Bodo Marks/picture alliance via Getty AstraZeneca’s respiratory portfolio is a little lighter as the British-Swiss pharmaceutical behemoth announced the offloading of two chronic obstructive pulmonary disease (COPD drugs) to fellow Swiss player Covis Pharma Group for $270 million. The agreement, announced November 1, involves Eklira (marketed as Tudorza in the U.S.) and Duaklir (marketed as Brimica® in some countries). The acquisition of the medicines – which netted AstraZeneca $143 million in the geographies covered under the agreement – provides a significant boost to Covis’s respiratory portfolio. COPD was the third leading cause of death worldwide in 2019, so the need and market are certainly there. “This acquisition represents a highly strategic and synergistic transaction with AstraZeneca, enabling Covis to offer a full continuum of best-in-class therapies for allergic rhinitis, asthma and COPD,” said Covis Chief Executive Officer Michael Porter in a statement. “As a result of the acquisition, Covis is firmly placed as one of the top 10 respiratory companies in the world.” Under the terms of the agreement, Covis will pay AstraZeneca $270 million upon completion of the deal, which is expected to close in quick order prior to the end of Q4 2021. In addition, Covis will be responsible for ongoing development costs related to the medicines. Eklira is a long-acting muscarinic antagonist (LAMA), while Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2-agonist. Both are presented as a dry powder for inhalation and delivered through a breath-actuated multi-dose dry powder inhaler called Genuair (Pressair in the US). AstraZeneca CEO Pascal Soriot has made no secret of his intention to steer the company's R&D pipeline to a predominantly oncology focus, and Covis is a repeat partner. In 2018, AstraZeneca divested three Asthma and Rhinitis Drugs to Covis for $350 Million. In this instance, the large multinational sold rights to Alvesco (ciclesonide), which is intended to treat persistent asthma, and Omnaris and Zetonna (ciclesonide), which are aimed at treating nasal symptoms associated with rhinitis. In April, Covis announced disappointing results from a Phase III trial evaluating Alvesco in COVID-19. The results were deemed not statistically significant, though Dr. Michael Blaiss, MD, clinical professor at the Medical College of Georgia at Augusta University in Augusta, Georgia and a member of the steering committee for the trial said that “further studies may want to look at whether this treatment may prevent or lessen post-acute COVID-19 syndrome.” AstraZeneca also said the deal will enable a sharpening of its focus on priority medicines in the respiratory and immunology space. The company went on to state in its official press release that the agreement “will ensure continued patient access to these established medicines.” With European headquarters in Zug as well as Amsterdam, Covis is a global specialty pharma company that markets therapeutics for patients with life-threatening conditions and chronic illnesses including asthma, COPD and anemia. Featured Jobs on BioSpace

Acquisition

18 Apr 2021

·www.globenewswire.com

COVIS PHARMA GROUP Announces Top-line Safety and Efficacy

ZUG, Switzerland, April 15, 2021 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced today top-line results from a 400 patient phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ciclesonide metered-dose inhaler in non-hospitalized patients 12 years of age and older with symptomatic COVID-19 infection. The primary endpoint of the study was time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, feeling feverish, repeated shaking with chills, muscle pain, headache, sore throat, and new loss of taste or smell, defined as symptom-free for a continuous period of ≥ 24 hours by Day 30. A sub-group analysis showed that time to alleviation of cough was the most improved symptom in the ciclesonide arm compared to the placebo arm by 6 days in 75% of the population. A relevant secondary efficacy endpoint reaching statistical significance (p=0.0301) was the 70% reduction observed in the ciclesonide arm versus 30% in the placebo arm of patients with subsequent emergency department visits or hospital admissions for reasons attributable to COVID-19 by Day 30. There were only a small number (n=10) of total events observed in this study. No new safety signals were identified with ciclesonide 320mcg twice daily for 30 days in the active comparator arm versus placebo. In addition, no new adverse events were reported after 60 days post treatment with ciclesonide. The study randomized 400 patients in a 1:1 ratio to ciclesonide versus placebo. The study demonstrated a treatment difference between ciclesonide (70.6%) and placebo (63.5%) in the percentage of patients with an improved time to alleviation of COVID-19 related symptoms, which was not statistically significant, with a p-value of 0.5502. “We are disappointed the results were not more positive, although there was a trend toward earlier cough cessation in the ciclesonide group. Further studies may want to look at whether this treatment may prevent or lessen post-acute COVID-19 syndrome,” said Michael Blaiss, MD, clinical professor at the Medical College of Georgia at Augusta University in Augusta, Georgia, a member of the steering committee for the trial. About AlvescoAlvesco (ciclesonide) Inhalation Aerosol is a glucocorticoid indicated for the long-term treatment of asthma as maintenance therapy in adults and adolescents 12 years of age and older in the U.S. and over 6 years of age in Canada. Alvesco Inhalation Aerosol is an inhaled glucocorticoid with a small particle size (1-2 μm) enabling it to reach areas of chronic inflammation in both the large and small airways. Alvesco is not indicated for the relief of acute bronchospasm. Alvesco is not indicated for children under 12 years of age in the U.S. or under the age of 6 in Canada. Canada Indication: ALVESCO is indicated for the prophylactic management of steroid-responsive bronchial asthma in adults, adolescents and children 6 years of age and older.Contraindications: United States of America Indication: ALVESCO is indicated for the maintenance treatment of asthma as prophylactic therapy in adults and adolescents 12 years of age and older.Important Limitations of USE: Important Safety Information for Alvesco (ciclesonide) Inhalation Aerosol Contraindications Warnings & Precautions Please read Important Safety Information and Full Prescribing Information for the US and Canada PM. About Covis Covis, with global operations in Zug, Switzerland, is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Additional information is available at . Trademarks are the property of their respective owners. Media Contactinfo@covispharma.com

100 Deals associated with Ciclesonide

External Link

KEGG	Wiki	ATC	Drug Bank
D01703	Ciclesonide	R01AD13 R03BA08	DB01410

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rhinitis, Allergic, Perennial	United States	Covis Pharma Holdings BV	20 Oct 2006
Rhinitis, Allergic, Seasonal	United States	Covis Pharma Holdings BV	20 Oct 2006
Asthma	Australia	CHIESI Farmaceutici SpA	24 Feb 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	United States	Covis Pharma Holdings BV	08 Jun 2020
Cough	Phase 3	Latvia	Sanofi-Aventis, Inc.	05 Jun 2006
Dyspnea	Phase 3	Latvia	Sanofi-Aventis, Inc.	05 Jun 2006
Pulmonary Disease, Chronic Obstructive	Phase 3	Latvia	Sanofi-Aventis, Inc.	05 Jun 2006
Seasonal rhinitis	Phase 3	United States	AstraZeneca PLC	01 Mar 2006
Childhood asthma	Phase 3	Brazil	AstraZeneca PLC	01 Oct 2004
Childhood asthma	Phase 3	Germany	AstraZeneca PLC	01 Oct 2004
Childhood asthma	Phase 3	Hungary	AstraZeneca PLC	01 Oct 2004
Childhood asthma	Phase 3	Poland	AstraZeneca PLC	01 Oct 2004
Childhood asthma	Phase 3	Portugal	AstraZeneca PLC	01 Oct 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04356495 (COVERAGE, ERS2023)	Phase 2/3	COVID-19	225	Placebo	ybrpjqhzol(jphwfcnycz) = inhaled IFN-β-1b, but not inhaled ciclesonide nor placebo, was linked to a decrease in plasma H3Cit levels (p: 0.02). rdhgsvuukw (tsztgtcvzy ) View more	Positive	09 Sep 2023
				Inhaled IFN-β-1b
NCT04381364 (HALT COVID-19, Pubmed \| BMJ Open)	Phase 2	COVID-19	98	Inhaled ciclesonide 320 µg	qzqkjnybcz(ujengsnyki) = raunfnrqvn rasmuqsufa (kxgzvrrfxn )	-	22 Feb 2023
				ciclesonide (Standard care)	qzqkjnybcz(ujengsnyki) = qblygtjadg rasmuqsufa (kxgzvrrfxn )
NCT04435795 (CONTAIN, CTgov)	Phase 2/3	COVID-19	215	Ciclesonide (Ciclesonide Inhaled and Nasal)	bqfqmvbzqe = kufqrrdsby kuclyaznst (wifdjwjppw, lxdrapxwkl - gagzecvhyu) View more	-	29 Apr 2022
				Normal Saline intranasal and placebo inhaler (Placebo)	bqfqmvbzqe = vdfczufvbx kuclyaznst (wifdjwjppw, ylczvtnmlw - xmefzzpkif) View more
NCT00458835 (BY9010/M1-422, CTgov)	Phase 4	Rhinitis, Allergic	30	Ciclesonide (Ciclesonide Nasal Spray)	szobnzhzkm(ubqijlumpo) = ptsthrkijh lbwqxudohi (qytklyxzcx, aykquldnjp - usujeaqjtj) View more	-	02 Mar 2022
				Ciclesonide (Ciclesonide Nasal Aerosol)	szobnzhzkm(ubqijlumpo) = nvtinmanip lbwqxudohi (qytklyxzcx, lundfoylnf - aznuofjvyu) View more
NCT04377711 (CTgov)	Phase 3	COVID-19	400	Ciclesonide (Group 1)	rycagfsghf(twayzxzjhv) = bhzklzmxsr zqaczxbgyj (nmqueabslh, rwdefujney - jewhkztdmu) View more	-	06 Jan 2022
				Placebo (Group 2)	rycagfsghf(twayzxzjhv) = mqhnvuyhqs zqaczxbgyj (nmqueabslh, zxxziimjqa - aeuedumvqt) View more
NCT04377711 (Pubmed \| JAMA Intern Med) Manual	Phase 3	COVID-19	400	Ciclesonide	yivnzerymx(oacjbdhobb) = cuipmmsahw suyslacxgq (maajmqoaou, 14.0 - 21.0)	Negative	22 Nov 2021
				Placebo	yivnzerymx(oacjbdhobb) = jnqqpjefzq suyslacxgq (maajmqoaou, 16.0 - 23.0)
NCT04435795 (CONTAIN, Pubmed \| BMJ)	Phase 2	COVID-19	203	Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily)	cpojukedam(njakdmanln) = gamnwxnbhd meamwfdmid (xsfwcqnjsz )	Negative	02 Nov 2021
				Metered dose inhaler and nasal saline placebos	cpojukedam(njakdmanln) = msefppthjh meamwfdmid (xsfwcqnjsz )
NCT04330586 (Pubmed \| J Clin Med) Manual	Phase 2	COVID-19	61	ciclesonide	nvvcgvgvyq(sskjgcpmoh) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. nfyzmxgagb (rpeaktqugu ) View more	Positive	12 Aug 2021
				standard care
NCT01455194 (CONTRAST, CTgov)	Phase 3	Asthma \| Persistent asthma	520	Ciclesonide (Treatment Period: Ciclesonide 160 mcg)	mdlukhhqsb(axunrahbob) = vvxaeuexqy hdbqvayfnc (onpklxcohp, 0.031) View more	-	25 Oct 2016
				Ciclesonide (Treatment Period: Ciclesonide 320 mcg)	mdlukhhqsb(axunrahbob) = tqfwbenkbv hdbqvayfnc (onpklxcohp, 0.035) View more
NCT02155881 (CTgov)	Phase 3	Rhinitis, Allergic, Seasonal	80	Ciclesonide (Ciclesonide 200 mcg)	ghmlzqzoam(patftrlajg) = lsckfgbnjw edefilwkuf (xcruqvootj, 1.83) View more	-	06 Oct 2016
				Ciclesonide Placebo (Placebo)	ghmlzqzoam(patftrlajg) = vytfvyrtii edefilwkuf (xcruqvootj, 1.63) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ciclesonide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation